KRMD

Business Context and Reporting Period

Company: Repro-Med Systems, Inc. (Note: Metadata listed "KORU Medical Systems," but the filing text identifies the registrant as Repro-Med Systems, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: May 31, 2009
Business Overview: The Company researches, develops, and markets medical devices, primarily the Freedom60 Syringe Infusion System for home care and the RES-Q-VAC Emergency Airway Suction System. It is classified as a smaller reporting company.

Key Financial Metrics

Debt Structure: Total long-term debt is approximately $795,374, consisting largely of loans from related parties (President and Director). A significant portion ($664,204) is a refinanced loan from a Director used to pay off a financial institution note.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 16% year-over-year, driven primarily by a 35% increase in Freedom60 sales due to Medicare specifications for subcutaneous immune globulin (SCIG) use.
• Product Mix Shift: While Freedom60 sales surged, RES-Q-VAC sales decreased 28% year-over-year, largely due to a 53% drop in international sales, partially offset by an 8% increase in domestic sales.
• Profitability: Net income decreased slightly by 1% ($64,053 vs. $64,784) despite higher operating profit. This was caused by a $21,959 provision for income taxes in the current quarter, compared to zero in the prior year.
• Expense Increases: Selling, General, and Administrative (SG&A) expenses rose 7% due to increased staff and benefits. Research and Development expenses more than doubled to $7,129 due to resource reallocation.
• Liquidity Improvement: Net cash provided by operating activities more than doubled to $97,344, attributed to aggressive accounts receivable follow-up and improved net income.

Outlook, Risks, and Contingencies

• Management Outlook: Management expects to meet financial needs for the next twelve months based on current capital and increased cash flow. They anticipate continued growth in the subcutaneous immune globulin market for the Freedom60.
• Government Grant: The Company received a $150,000 grant from the Trade Adjustment Assistance Program (50% match) for marketing and regulatory affairs. Approximately $55,000 in payment assistance remains available.
• Key Risks:
  • Reimbursement Dependence: Sales are heavily reliant on Medicare reimbursement codes (HCPCS E0779). Changes in policy could adversely affect sales.
  • Competition: Low-cost Chinese competitors exist for the RES-Q-VAC. New drugs (e.g., Hyaluronidase) could alter market conditions for the Freedom60.
  • Liquidity: The Company has a history of operating losses and relies on related-party financing. Limited liquidity is cited as a risk factor.
• Contingencies: The Company is contingently liable for approximately $33,600 in rework costs for a customer order, which has been provisioned in the financial statements.
• Subsequent Events: In June 2009, the Company issued shares to a Director to satisfy a portion of a related-party loan.

Investor Verification Checklist

• Related Party Debt: Verify the terms and repayment status of the $664,204 loan from a Director and the $100,000 loan from the President, which constitute the majority of debt.
• Medicare Coding Stability: Confirm the continued validity of HCPCS code E0779 for Freedom60 reimbursement, as this is a primary revenue driver.
• Grant Utilization: Monitor the utilization of the remaining $55,000 from the Trade Adjustment Assistance Program and its impact on future R&D and marketing costs.
• International Sales Recovery: Assess the strategy to recover the 53% decline in international RES-Q-VAC sales.
• Stock Issuance for Debt: Review the impact of the June 2009 share issuance to the Director on shareholder dilution and debt reduction.